Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antiplatelet and Anticoagulant therapeutic - Aplagon/Cadila Pharmaceuticals

Next Previous
Search
Drug Profile

Antiplatelet and Anticoagulant therapeutic - Aplagon/Cadila Pharmaceuticals

Alternative Names: APAC

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aplagon
  • Developer Aplagon; Cadila Pharmaceuticals
  • Class Anticoagulants; Antiplatelets; Antithrombotics; Vascular disorder therapies
  • Mechanism of Action Heparin antagonists; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Renal failure
  • Phase 0 Peripheral arterial occlusive disorders

Most Recent Events

  • 03 Feb 2025 Aplagon plans a phase-IIa trial for Peripheral arterial occlusive disorders in France (IV) ,
  • 24 Oct 2024 Aplagon initiates a phase I trial in volunteers (IV), prior to October 2024
  • 28 Mar 2024 No recent reports of development identified for preclinical development in Thrombosis (Prevention) in Finland

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top